Evidence map›Paper›PMID 33256496›Full record

ReviewJournal of neurotrauma2021

Use of Medical Cannabis to Treat Traumatic Brain Injury.

Danielle C Hergert, Cidney Robertson-Benta, Veronik Sicard, Daniela Schwotzer, Kent Hutchison, Dan P Covey, Davin K Quinn, Joseph R Sadek, Jacob McDonald, Andrew R Mayer

Open access · greenAbstract readReview
In one paragraph

Review in Journal of neurotrauma, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 41 citations in OpenAlex.

  1. Review
  2. The Influence of Cannabinoids onCannabis and cannabinoid research · 2024
    Article
  3. Article
  4. Traumatic Brain Injury Outcomes After Recreational Cannabis Use.Neuropsychiatric disease and treatment · 2024
    Article
  5. Recent Research onMolecules (Basel, Switzerland) · 2023
    Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Danielle C HergertThe Mind Research Network/Lovelace Biomedical and Environmental Research Institute, Pete & Nancy Domenici Hall, Albuquerque, New Mexico, USA.
Cidney Robertson-BentaThe Mind Research Network/Lovelace Biomedical and Environmental Research Institute, Pete & Nancy Domenici Hall, Albuquerque, New Mexico, USA.
Veronik SicardThe Mind Research Network/Lovelace Biomedical and Environmental Research Institute, Pete & Nancy Domenici Hall, Albuquerque, New Mexico, USA.
Daniela SchwotzerLovelace Biomedical and Environmental Research Institute, Albuquerque, New Mexico, USA.
Kent HutchisonDepartment of Psychology and Neuroscience, University of Colorado, Boulder, Colorado, USA.
Dan P CoveyLovelace Biomedical and Environmental Research Institute, Albuquerque, New Mexico, USA.
Davin K QuinnDepartment of Neurology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.
Joseph R SadekDepartment of Neurology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.
Jacob McDonaldLovelace Biomedical and Environmental Research Institute, Albuquerque, New Mexico, USA.
Andrew R MayerThe Mind Research Network/Lovelace Biomedical and Environmental Research Institute, Pete & Nancy Domenici Hall, Albuquerque, New Mexico, USA.
Mental Research Institute · USUniversity of New Mexico · USUniversity of Colorado Boulder · US

Funding

The Impact of Diffuse Mild Brain Injury on Clinical Outcomes in ChildrenR01NS098494 · NINDS · THE MIND RESEARCH NETWORK · PI Andrew Robert Mayer · 2016 to 2026
$7.6M
NINDS NIH HHS R01 NS098494
6 · The paper itself

Abstract

There is not a single pharmacological agent with demonstrated therapeutic efficacy for traumatic brain injury (TBI). With recent legalization efforts and the growing popularity of medical cannabis, patients with TBI will inevitably consider medical cannabis as a treatment option. Pre-clinical TBI research suggests that cannabinoids have neuroprotective and psychotherapeutic properties. In contrast, recreational cannabis use has consistently shown to have detrimental effects. Our review identified a paucity of high-quality studies examining the beneficial and adverse effects of medical cannabis on TBI, with only a single phase III randomized control trial. However, observational studies demonstrate that TBI patients are using medical and recreational cannabis to treat their symptoms, highlighting inconsistencies between public policy, perception of potential efficacy, and the dearth of empirical evidence. We conclude that randomized controlled trials and prospective studies with appropriate control groups are necessary to fully understand the efficacy and potential adverse effects of medical cannabis for TBI.

Indexed as

Brain Injuries, TraumaticCannabinoidsHumansMedical MarijuanaCannabinoidsMedical Marijuanacannabidiolcannabinoidsmedical cannabismedical marijuanaTHCtraumatic brain injury

Identifiers

PMID33256496
PMCPMC8260892
OpenAlexW3109479310

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.